{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:05:08Z","timestamp":1794459908755,"version":"4.9.1"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009729","name":"Ludwig Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0713-y","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T13:35:17Z","timestamp":1567776917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9713-1872","authenticated-orcid":false,"given":"Ashray","family":"Gunjur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"issue":"7","key":"713_CR1","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Yucai Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(7):1008\u20131019.","journal-title":"JAMA Oncology"},{"key":"713_CR2","first-page":"212","volume":"21","author":"MB Schmidt","year":"1926","unstructured":"Schmidt MB. Eine biglandulare Erkrankung (Nebennieren und Schilddruse bei Morbus Addisonni). Dtsch Pathol Ges. 1926;21:212\u201321.","journal-title":"Dtsch Pathol Ges"},{"issue":"3","key":"713_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1210\/edrv.23.3.0466","volume":"23","author":"C Betterle","year":"2002","unstructured":"Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune Polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002;23(3):327\u201364.","journal-title":"Endocr Rev"},{"issue":"12","key":"713_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMra1713301","volume":"378","author":"ES Husebye","year":"2018","unstructured":"Husebye ES, Anderson MS, K\u00e4mpe O. Autoimmune Polyendocrine Syndromes. N Engl J Med. 2018;378(12):1132\u201341.","journal-title":"N Engl J Med"},{"issue":"8","key":"713_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"Angeliki M. Stamatouli","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471\u201380.","journal-title":"Diabetes"},{"issue":"4","key":"713_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1399-0039.2011.01634.x","volume":"77","author":"C. Weinstock","year":"2011","unstructured":"Weinstock C, Matheis N, Barkia S, Haager M-C, Janson A, Markovi\u0107 A, et al. Autoimmune polyglandular syndrome type 2 shows the same HLA class II pattern as type 1 diabetes\u2020. Tissue Antigens. 2011;77(4):317\u201324.","journal-title":"Tissue Antigens"},{"issue":"1","key":"713_CR7","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","volume":"7","author":"Hye In Kim","year":"2017","unstructured":"Kim HI, Kim M, Lee S-H, Park SY, Kim YN, Kim H, et al. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. OncoImmunology. 2018;7(1):e1375642.","journal-title":"OncoImmunology"},{"issue":"2","key":"713_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1210\/js.2018-00366","volume":"3","author":"G Lanzolla","year":"2019","unstructured":"Lanzolla G, Coppelli A, Cosottini M, Del Prato S, Marcocci C, Lupi I. Immune checkpoint blockade anti\u2013PD-L1 as a trigger for autoimmune Polyendocrine syndrome. J Endocr Soc. 2019 Feb 1;3(2):496\u2013503.","journal-title":"J Endocr Soc"},{"issue":"1","key":"713_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1620\/tjem.244.33","volume":"244","author":"K Sakurai","year":"2018","unstructured":"Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z. Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, Nivolumab. Tohoku J Exp Med. 2018;244(1):33\u201340.","journal-title":"Tohoku J Exp Med"},{"issue":"11","key":"713_CR10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","volume":"66","author":"Marie-L\u00e9a Gauci","year":"2017","unstructured":"Gauci M-L, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, et al. Autoimmune diabetes induced by PD-1 inhibitor\u2014retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother. 2017;66(11):1399\u2013410.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"6","key":"713_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1210\/js.2017-00170","volume":"1","author":"Anne-C\u00e9cile Paepegaey","year":"2017","unstructured":"Paepegaey A-C, Lheure C, Ratour C, Lethielleux G, Clerc J, Bertherat J, et al. Polyendocrinopathy resulting from Pembrolizumab in a patient with a malignant melanoma. J Endocr Soc. 2017;1(6):646\u20139.","journal-title":"Journal of the Endocrine Society"},{"issue":"1","key":"713_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000456540","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Masood A, Bari S, Yavuz S, Grosbach AB. Autoimmune diabetes and thyroiditis complicating treatment with Nivolumab. Case Rep Oncol. 2017;10(1):230\u20134.","journal-title":"Case Rep Oncol"},{"issue":"1","key":"713_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.diabet.2016.05.007","volume":"43","author":"M Alhusseini","year":"2017","unstructured":"Alhusseini M, Samantray J. Autoimmune diabetes superimposed on type 2 diabetes in a patient initiated on immunotherapy for lung cancer. Diabetes Metab. 2017;43(1):86\u20138.","journal-title":"Diabetes Metab"},{"issue":"1","key":"713_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","volume":"4","author":"JR Lowe","year":"2016","unstructured":"Lowe JR, Perry DJ, Salama AKS, Mathews CE, Moss LG, Hanks BA. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer. 2016;4(1):89.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"713_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00592-016-0872-y","volume":"53","author":"SH Kong","year":"2016","unstructured":"Kong SH, Lee SY, Yang YS, Kim TM, Kwak SH. Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes. Acta Diabetol. 2016;53(5):853\u20136.","journal-title":"Acta Diabetol"},{"issue":"6","key":"713_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-016-1835-4","volume":"65","author":"E Hansen","year":"2016","unstructured":"Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. 2016;65(6):765\u20137.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"713_CR17","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.2337\/dc15-0889","volume":"38","author":"Mahnaz Mellati","year":"2015","unstructured":"Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, et al. Anti\u2013PD-1 and anti\u2013PDL-1 monoclonal antibodies causing type 1 diabetes. Diabetes Care. 2015;38(9):e137\u20138.","journal-title":"Diabetes Care"},{"key":"713_CR18","doi-asserted-by":"crossref","unstructured":"Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):e55\u20137.","DOI":"10.2337\/dc14-2349"},{"issue":"7528","key":"713_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"Paul C. Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"1","key":"713_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"Willy Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"},{"issue":"4","key":"713_CR21","doi-asserted-by":"publisher","first-page":"998-1013.e20","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"Moshe Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175(4):998\u20131013.e20.","journal-title":"Cell"},{"issue":"12","key":"713_CR22","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","volume":"24","author":"Yinghong Wang","year":"2018","unstructured":"Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804.","journal-title":"Nature Medicine"},{"issue":"6375","key":"713_CR23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"Diego Chowell","year":"2017","unstructured":"Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582\u20137.","journal-title":"Science"},{"issue":"7","key":"713_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"Fiamma Berner","year":"2019","unstructured":"Berner F, Bomze D, Diem S, et al. Association of Checkpoint Inhibitor\u2013Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non\u2013Small Cell Lung Cancer. JAMA Oncol. 2019;5(7):1043\u20131047.","journal-title":"JAMA Oncology"},{"key":"713_CR25","doi-asserted-by":"crossref","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.","DOI":"10.1186\/s40425-017-0300-z"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0713-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T19:12:30Z","timestamp":1664305950000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0713-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0713-y","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"30 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient signed informed consent to participate in the \u201cBiomarkers in Cancers\u201d study (approved by the Austin Health human research ethics committee) which involves consent for research blood tests including HLA testing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient has signed the consent form for the full publication of this case report (available on request).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}